Health & Fitness
Fri, May 25, 2012
NEEDHAM, Mass.--([ BUSINESS WIRE ])--Celldex Therapeutics, Inc. (Nasdaq: CLDX) will host a conference call at 4:30 P.M. Eastern Time on Wednesday, May 23, 2012 to announce interim, topline results of the Phase 2b EMERGE study of CDX-011 in patients with advanced breast cancer. Linda Vahdat, MD, Professor of Medicine, Chief of Solid Tumor Service and Director of the Breast Cancer Research Program at Weill Cornell Medical College and the lead investigator of the EMERGE study, will join Celldex management on the webcast to discuss data from the study.
The conference call will be webcast live over the Internet and can be accessed by logging on to the "News & Events" section of the Celldex Therapeutics website at [ www.celldextherapeutics.com ]. The call can also be accessed by dialing 800-299-0148 (within the United States) or 617-801-9711 (outside the United States). The passcode for participants is 98560829.
A replay of the call will be available approximately two hours after the live call concludes through June 6, 2012. To access the replay, dial 888-286-8010 (within the United States) or 617-801-6888 (outside the United States). The passcode is 41731858. The webcast will also be archived on the Companyas website.
About Celldex Therapeutics, Inc.
Celldex Therapeutics is the first antibody-based combination immunotherapy company. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused Precision Targeted Immunotherapy (PTI) Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators used in optimal combinations to create novel disease-specific drug candidates. For more information, please visit [ http://www.celldextherapeutics.com ].
